Aarbakke J. Melatonin: Myter og virkelighet. Tidsskr Nor Lægefor 116:14:1660, 1996.
Abe M, Reiter RJ, and Poeggeler B. Inhibitory effect of melatonin on cataract formation in newborn rats: Evidence for an antioxidative role for melatonin. J Pin Res 17(2):94-100, 1994.
Aldous M et al. Plasma concentrations of melatonin in man following oral absorption of different preparations. Brit J Clin Pharmacol 19:517-521, 1985.
Almay BGL, Von Knorring L, and Wetterberg L. Melatonin in serum and urine in patients with idiopathic pain syndromes. Psych Res 22:179-191, 1987.
Anton-Tay F et al. On the effect of melatonin upon human brain. Its possible therapeutic implications. Life Sci 10(1):841-850, 1971.
Aoyama H, Mori N, and Mori W. Effects of melatonin on genetic hypercholesterolemia in rats. Atheroscl 69:269-272, 1988.
Arendt J et al. Alleviation of jet lag by melatonin: Preliminary results of controlled double blind trial. Brit Med J 292:1170, 1986.
Atroshi F, Rizzo A, Westermarck T, and Ali-Vehmas T. Effects of tamoxifen, melatonin, coenzyme Q10, and l-carnitine supplementation on bacterial growth in the presence of mycotoxins. Pharmacol Res 38:4:289-295. 1998.
Barchas J, DaCosta F, and Spector S. Acute Pharmacology of melatonin. Nature 214:191-920, 1967.
Barlow-Walden LR, Reiter RJ, and Poeggeler B. Effects of melatonin on brain glutathione peroxidase activity. Dept. Cell Struct Biol, UTH Sci Cent, 1995.
Bartsch C et al. Depression of melatonin in patients with primary breast cancer. Cancer 67:1681-1684, 1991.
Beck-Friis J, Kjellman BF, and Wettenberg L. Serum melatonin in relation to clinical variables in patients with major depressive disorder, and a hypothesis of a low melatonin syndrome. Acta Psych Scand 71:319-330, 1985.
Bellipanni G, Bianchi P, Pierpaoli W, et al. Effects of melatonin in perimenopausal and menopausal women: a randomized and placebo controlled study. Exp Gerontol 2001;36(2):297-310.
Ben-Nathan D, Maestroni Gj, and Conti A. Protective effects of melatonin in mice infected encephalitis viruses. Arch Vir 140:223-230, 1995.
Blask DE and Hill SM. Effects of melatonin on cancer: Studies on MCF-7 human breast cancer cells in culture. J Neur Transm 21:433-449, 1986.
Brugger P, Marktl W, and Herold M. Impaired nocturnal secretion of melatonin in coronary heart disease. Lancet, June 3;345:1408, 1995.
Cagnacci A, Elliott JA, and Yen SS. Melatonin: A major regulator of the circadian rhythm of core temperature in humans. J Clin Endocrinol Metabol 75(2):447-452, 1992.
Carnacci A et al. The effect of light on core body temperature is mediated by melatonin in women. J Clin Endocrinol Metabol 76:1036-1038, 1993.
Caroleo MC, Frasca D, and Doria G. Melatonin as immunomodulator in immunodeficient mice. Immunopharmacol 23:81-89, 1992.
Caroleo MC, Doria G, and Nistico G. Melatonin restores immunodepression in aged and cyclophosphamidetreated mice. Ann NY Acad Sci 31(719):343-352, 1994.
Cavallo A, Holt KG, and Meyer WJ. Melatonin circadian rhythm in childhood depression. J Am Acad Child Adol Psych 26(3):395-399, 1987.
Cavallo A. Melatonin and human puberty: Current perspectives. J Pin Res 15:115-121, 1993.
Cerea G, Vaghi M, Ardizzoia A, et al. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Anticancer Res. 2003; 23(2C):1951-4.
Claustrat B, Brun J, David M, et al. Melatonin and jet lag: Confirmatory result using a simplified protocol. Biol Psych 1992;32(8):705-11.
Conti A, Maestroni GJ. Role of the pineal gland and melatonin in the development of autoimmune diabetes in non-obese diabetic mice. J Pin Res 20:3:164-72, 1996.
Copinschi G and Van Cauter E. Effetcs of ageing on modulation of hormonal secretions by sleep and circadian rhythmicity. Hormone Res 43:20-24, 1995.
Cos S, Blask DE, and Hill SM. Effects of melatonin on the cell cycle kinetics and "estrogen-resque" of MCF-7 human breast cancer cells in culture. J Pin Res 10:36, 1991.
Cos S, and Sanchez-Barcelo EJ. Differences between pulsatile or continuous exposure to melatonin on MCF-7 breast cancer cell proliferation. Cancer Let 85:105-109, 1994.
Cos S and Blask DE. Melatonin modulates growth factor activity in MCF-7 human breast cancer cells. J Pin Res 17(1), 25-32, 1994.
Cramer H, Rudolph J, and Kendel K. On the effects of melatonin on sleep and behavior in man. Adv Biochem Psychopharmacol 11:187-191, 1974.
Crespo D et al. Interaction between melatonin and estradiol on morphological and morphometric features of MCF-7 human breast cancer cells. J Pin Res 16:215-222, 1994.
Cunnane SC, Manku MS, and Horrobin DF. Enhanced vascular reactivity to various vasoconstrictor agents following pinealectomy in the rat: Role of melatonin. Cancer J Phys Pharmacol 58:287-293, 1980.
Czeisler CA et al. Suppression of melatonin secretion in some blind patients by exposure to bright light. New Engl J Med 332(1), 6-11, Jan. 1995.
Dahlitz M, Alvarez B, Vignau J, English J, et al. Delayed sleep phase syndrome response to melatonin. Lancet 337: 8750: 1121-1124, 1991.
Danilenko KV et al. Diurnal and seasonal variations of melatonin and serotonin in women with seasonal affective disorder. Arct Med Res 53(3), 137-145, July 1994.
Davis R. Light exposure and breast cancer. Epidemiol 458, 1991.
Davis S, Mirick D.K, and Stevens R.G: Night Shift Work, Light at Night, and Risk of Breast Cancer, J Natl Cancer Inst 2001 93: 1557-1562.
De La Lastra CA, Cabeza J, Motilva V, and Martin MJ. Melatonin protects against gastric ischemia-reperfusion injury in rats. J Pin Res 23:2:47-52, 1997.
Dkahlitz M, Alvarez B, Vignau J et al. Delayed sleepphase syndrome response to melatonin. Lancet 37, May 1991.
Dollins AB et al. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci USA, 91:1824-1828, 1994.
Field R. Melatonin may relieve sleep-cucle disorders. Med Trib 2, April 1993.
Frederiksen T and Pless G. Antioxidantive potential of melatonin and pinoline in lipid peroxidation of brain tissue. Master's thesis:1-52, App., 1998.
Furuya Y et al. 5-fluorouracil attenuates an oncostatic effect of melatonin on estrogen-sensitive human breast cancer cells (MCF-7). Cancer Lett 81(1), 95-98, 1994.
Garcia-Maurino S, Gonzalez-Haba MG, Calvo JR, Rafii-El-Idrissi M et al. Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4+ cells: a possible nuclear receptor- mediated mechanism involving T helper type 1 lymphocytes and monocytes. J Immunol 159:2:574-581, 1997.
Garfinkel D, Laudon M, Nof D, and Zisapel N. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 346:8974:541-544, 1995.
Garfinkel D, Zisapel N, Wainstein J, and Laudon M. Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Arch Intern Med 159:20:2456-60, 1999.
Haimov I et al. Sleep disorders and melatonin rhythms in elderly people. BMJ 309:167, 1994.
Haimov I et al. Melatonin replacement therapy of elderly insomniacs. Sleep 18:598-603, 1995.
Hansen J: Light at Night, Shiftwork, and Breast Cancer Risk, J Natl Cancer Inst 2001 93: 1513-1515.
Hansen T, Bratlid T, and Brenn T. Midwinter insomnia in the subarctic region: Evening levels of serum melatonin and cortisol before and after treatment with bright artificial light. Acta Psychiatr Scand 75:428-434, 1987.
Hardeland R et al. The significance of the metabolism of the neurohormone melatonin: Antioxidative protection and formation of bioactive substances. Neurosci Biobehav Rev 17, 347-357, 1993.
Harma M et al. The effect of 4-day round trip flights over 10 time zones on the circadian variation of salivary melatonin and cortisol in airline flight attendants. Ergonom 37, 1479-1489, 1993.
Harman D. Free radical theory of aging. Mutat Res 275:257-266, 1992.
Hattori A et al. Identification of melatonin in plants and its effects on plasma melatonin levels and binding receptors in vertebrates. Biochem Mol Biol Int 35:627-634, 1995.
Hill SM et al. The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. Cancer Lett 64, 249-256, 1992.
James SP. Melatonin administration in insomnia. Neuropsychopharmacol 3(1):19-22, 1990.
Jan JE, Espezel H, and Appleton RE. The treatment of sleep disorders with melatonin. Devel Med Child Neurol 36:97-107, 1994.
Kane MA, Johnson A, and Robinson WA. Serum melatonin levels in melanoma patients after repeated oral administration. Melano Res 4:59-65, 1994.
Kennedy SH, Tighe S, and Brown GM. Melatonin and cortisol "switches" during mania, depression, and euthymia in a drug-free bipolar patient. J Nervous Mental Dis 177(5):300-303, 1989.
Kennedy SH. Melatonin disturbances in anorexia nervosa and bulimia nervosa. Int J Eat Disord 16(3): 257-265, Nov. 1994.
Kerenyi NA, Pandula E, Feuer G. Why the incidence of cancer is increasing: The role of "light pollution". Med Hypotheses 33: 2:75-78, 1990.
Kliukiene K, Tynes T, Andersen A. Risk of breast cancer among Norwegian women with visual impairment. British Journal of Cancer 2001;84: 397-399.
Kloog I, Haim A, Stevens RG, Portnov BA. Global Co-Distribution of Light at Night (LAN) and Cancers of Prostate, Colon, and Lung in Men. Chronobiol Int. 2009;26(1):108-25.
Krauchi K, Wirz-Justice A, and Graw P. The relationship of affective disorder state to dietary preference: Winter depression and light therapy as a model. J Affeect Disor 20:43-53, 1990.
Laughlin GA, Loucks AB, and Yen SSC. Marked augmentation of nocturnal melatonin secretion in amenorrheic athletes, but not in cycling athletes: Unaltered by opioidergic or dopaminergic blockade. J Clin Endocrinol Metabol 73(6):1321-1326, 1991.
Lerner AB, and Case JD. Melatonin. Fed Proc 19(2):590-592, 1960.
Lesnikov VA, Korneva EA, Dall'Ara A et al. The involvement of pineal gland and melatonin in immunity and aging. II. Thyrotropin releasing hormone and melatonin forestall involution and promote reconstitution of the thymus in anterior hypothalamic area (AHA)-lesioned mice. Int J Neuro Sci 62:141-153, 1992.
Lewy AJ, Wehr TA, and Goodwin FK. Light suppresses melatonin secretion in humans. Sci 210, Dec. 1980.
Lewy AJ, Kern HA, Rosenthal NE, and Wehr TA. Bright artificial light treatment of a manic-depressive patient with a seasonal mood cycle. Am J Psych 139(11):1496-1498, 1982.
Lindevall K. Melatonin: a multi-faceted hormone but not a wonder drug. Tabu 2:41, 1996.
Lino A, Silvo S, and Ruscuni A. Melatonin and jet lag: Treatment schedule. Biol Psych 34: 587-588, 1993.
Lissoni P, Barni S, Tancini G, and Fraschini F. Clinical study of melatonin in untreatable advanced cancer patients. Tumori 73:475-480, 1987.
Lissoni P, Crispino S, Barni S et al. Pineal gland and tumour cell kinetics: Serum levels of melatonin in relation to Ki-67 labelling rate in breast cancer. Oncol 47(3):275-277, 1990.
Lissoni P, Barni S, Ardizzoia A, Maestroni GJM, et al. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin. Oncol 49:336-339, 1992.
Lissoni P, Barni S, Ardizzoia A, Brivio F, et al. Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients. J Biol Regul Homeost Agents 6:4:132-136, 1992.
Lissoni P, Tisi E, Barni S, Ardizzoia A, et al. Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer. Br J Cancer 66:1:155-158, 1992.
Lissoni P, Barni S, Tancini G, Ardizzoia A, Rovelli F, Cazzaniga M, Brivio F, Piperno A, Aldeghi R, Fossati D, et al. Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract. Br J Cancer 67:6:1404-1407, 1993.
Lissoni P, Barni S, and Tancini G. Efficacy of the concomitant in cancer immunotherapy with low-dose IL-2 in patients with advanced solid tumors who had progressed on IL-2 alone. Oncol 51:344-347, 1994.
Pineal-opioid system interactions in the control of immunoinflammatory responses. Ann NY Acad Sci 471:191-196, 1994.
Lissoni P, Barni S, Ardizzoia A, Tancini G, et al. A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. Cancer 73:3:699-701, 1994.
Lissoni P, Meregalli S, Fossati V, Paolorossi F, et al. A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer. Tumori 80:6:464-467, 1994.
Lissoni P, Barni S, Brivio, and Maestoni GJ. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer 1994; 69:196-199.
Lissoni P, Barni S, Meregalli S, Fossati V, Cazzaniga M, Esposti D, and Tancini G. Modulation of cancer endocrine therapy by melatonin: A phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer 1995; 71:4:854-856.
Lissoni P, Ardizzoia A, Barni S, Brivio F, Tisi E, Rovelli F, Tancini G, Maestroni G, and Fumagalli L. Efficacy and tolerability of cancer neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin: a progress report of 200 patients with advanced solid neoplasms. Oncol Rep 1995; 2:1063-1068.
Lissoni P, Barni S, Fossati V, Ardizzoia A, Cazzaniga M, Tancini G, and Frigerio F. A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour. Supp Care Cancer 1995; 3:194-197.
Lissoni P. Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone. Eur Urol 1997; 31:178-181.
Lissoni P, Giani L, Zerbini S, Trabattoni P, et al. Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms. Nat Immun 1998; 16:1:27-33.
Longoni B, Salgo MG, Pryor WA, and Marchiafava PL. Effects of melatonin on lipid peroxidation induced by oxygen radicals. Life Sci 1998;62:10:853-859.
Lopez PM, Finana IT, De Agueda MC, Sanchez EC, et al. Protective effect of melatonin against oxidative stress induced by ligature of extra-hepatic biliary duct in rats. J Pineal Res 2000; 28:3:143-9.
Maestroni GJ, Conti A, and Pierpaoli W. Pineal melatonin, its fundamental immunoregulatory role in aging and cancer. Annals NY Acad Sci 1988; 521:140-148.
Maestroni GJ and Conti A. Anti-stress role of the melatonin-immuno-opioid network: Evidence for a physiological mechanism involving T-cell-derived, immunoreactive B-endorphin and metenkephalin binding the thymic opioid receptors. Int J Neuro Sci 1991; 61:289-298.
Maestroni GJ. The immunoneuroendocrine role of melatonin. J Pin Res 1993; 14:1-10.
Maestroni GJ. Melatonin regulation of endogenous T-cell derived hematopoietic cytokines. Cancer Res 1994;54:2429-2432.
Maestroni GJ, Conti A, and Lissoni P. Colony-stimulating activity and hematopoietic resque from cancer chemotherapy compounds are induced by melatonin via interleukin-4. Cancer Res 1994; 54(17):4740-4743.
Maestroni GJ. T-helper-2 lymphocytes as peripheral target of melatonin signaling. J Pin Res 1995; 18:84-89.
Mallo C et al. Effects of a four-day nocturnal melatonin treatment on the 24 h plasma melatonin, cortisol and prolactin profiles in humans. Acta Endocrinol 119: 474-480, 1988.
Manda K, Bhatia AL. Melatonin-induced reduction in age-related accumulation of oxidative damage in mice. Biogerontology. 2003;4(3):133-9.
Mawson AR. Breast cancer in female flight attendants. Lancet 1998: 352:626.
McIntyre IM, Norman TR, and Burrows GD. Melatonin supersensitivity to dim light in seasonal affective disorder. Lancet 1990: 335:448.
Menendez-Pelaez A, and Reiter RJ. Distribution of melatonin in mammalian tissues: The relative importance of nuclear versus cytosolic localization. J Pin Res 1993; 15:59-69.
Mishima K et al. Morning bright light therapy for sleep and behavior disorders in elderly patients with dementia. Acta Psych 89(1), 1-7, 1994.
Molina-Carballo A, Munoz-Hoyos A, Rodriguez-Cabezas T, and Acuna-Castroviejo D. Day-night variations in melatonin secretion by the pineal gland during febrile and epileptic convulsions in children. Psychiatr Res 52:3:273-283, 1994.
Mori N, Aoyama H, and Mori W. Anti-hypercholesterolemic effect of melatonin in rats. Jap Soc Pathol 39:613-618, 1989.
Mori W, Aoyama H, and Mori N. Melatonin protects rats from injurious effects of glucocorticoid, dexamethasone. Jap J Exp Med 54(6):255-261, 1984.
Morrey KM, McLachlan JA, and Bakouche O. Activation of human monocytes by the pineal hormone melatonin. J Immunol 153:2671-2680, 1994.
Muller-Wieland D, Behnke B, and Krone W. Melatonin inhibits LDL receptor activity and cholesterol synthesis in freshly isolated human mononuclear leukocytes. Biochem Biophys Res Commun 203(1):416-421, 1994.
Murch SJ, Simmons CB, and Saxena PK. Melatonin in feverfew and other medicinal plants. Lancet 350:1598-99, 1997.
Murialdo G, Castelli P, and Dolleri A. Circadian secretion of melatonin and thyrotropin in hospitalized aged patients. Aging Clin Exper Res 5(1):39-46, Feb. 1993.
Møller M. Melatonin, koglekirtlen og "hjernens indre ur". Lægemag 7:30-33, 1996.
Møller M. Melatonin. Ugeskr Læger 159:12:1737-1739, 1997.
Nave R, Peled R, and Lavie P. Melatonin improves evening napping. Eur J Pharmacol 275:213-216, 1995.
Neri B, Brocchi A, and Cagnoni M. Effects of melatonin administration on cytokine production in patients with advanced solid tumors. Oncol Rep 2:45-47, 1995.
Neri B, de Leonardis V, Gemelli MT, di Loro F, et al. Melatonin as biological response modifier in cancer patients. Anticancer Res 18:2B:1329-1332, 1998.
Nordlund JJ and Lerner AB. The effects of oral melatonin on skin color and on the release of pituitary hormones. J Clin Endocrinol Metab 45(4):768-774, 1976.
Nordlund JJ, Lerner AB. The effects of oral melatonin on skin color and on the release of pituitary hormones. J Clin Endocrinol Metabol 45:4:768-774, 1978.
Ochitill H et al. Psychotropic drug prescribing for hospitalized patients with acquired immunodeficiency. Am J Med 90(5):601-605, 1991.
Panzer A. Depression or cancer: the choice between serotonin and melatonin? Med Hypoth 50:385-387, 1998.
Petrie K et al. a double-blind trial of melatonin as a treatment for jet lag in international cabin crew. Biol Psych 33, 526-530, 1993.
Pieri C, Marra M, Moroni F, and Marcheselli F. Melatonin: A peroxyl radical scavenger more effective than vitamin E. Pergamon 55(15):271-276, 1994.
Pierpaoli W and Yi CX. The involvement of pineal gland and melatonin in immunity and aging. I. Thymus-mediated, immunoreconstituting and antiviral activity of thyrotropin releasing hormone. J Neuroimmun 27:99-109, 1990.
Pierpaoli W, Dall'Ara A, and Pedrinis et al. The pineal control of aging: The effects of melatonin and pineal grafting on the survival of older mice. In Physiological Senescence and its postponement: Theoretical approaches and rational interventions. Acad. Sci. 621:291-313, 1991.
Pierpaoli W and Regelson W. Pineal control of aging: effect of melatonin and pineal grafting on aging mice. Proc Natl Acad Sci USA 94:787-791, 1994.
Pierrefiche G, Topall G, Courboin G, Henriet I, et al. Antioxidant activity of melatonin in mice. Res Commun Chem Pathol Pharmacol 80:2:211-223, 1993.
Poeggeler B, Saarela S, Reiter RJ, Tan DX, et al. Melatonin -- a highly potent endogenous radical scavenger and electron donor: new aspects of the oxidation chemistry of this indole accessed in vitro. Ann N Y Acad Sci 738:419-420, 1994.
Rao ML et al. The influence of phototherapy on serotonin and melatonin in non-seasonal depression. Pharmaco-psych 23:155-158, 1990.
Rao ML et al. Blood serotonin,, serum melatonin and light therapy in healthy subjects and in patients with non-seasonal depression. Acta Psychiatr Scand 86:127-132, 1992.
Reiter RJ. Interactions of the pineal hormone melatonin with oxygen-centered free radicals: A brief review. Braz J Med Biol Res 26:1141-1155, 1993.
Reiter RJ, Tan DX, Poeggeler B, Menendez-Pelaez A, Chen LD, and Saarela S. Melatonin as a free radical scavenger: implications for aging and age-related diseases. Ann N Y Acad Sci 719:1-12, 1994.
Reiter RJ. Functional pleiotropy of the neurohormone melatonin: antioxidant protection and neuroendocrine regulation. Front Neuroendocrinol 16:4:383-415, 1995.
Reiter RJ et al. Oxygen radical detoxification processes during aging: The functional inportance of melatonin. Aging Clin Exp Res 7:340-351, 1995.
Reiter RJ. Oxidative processes and antioxidative defense mechanisms in the aging brain. FASEB J 9:7:526-533, 1995.
Reiter RJ. The pineal gland and melatonin in relation to aging: a summary of the theories and of the data. Exp Gerontol 30:3-4:199-212, 1995.
Reiter RJ. The role of the neurohormone melatonin as a buffer against macromolecular oxidative damage. Neurochem Int 27:6:453-460, 1995.
Reiter RJ, Melchiorri D, Sewerynek E, Poeggeler B, Barlow-Walden L, Chuang J, Ortiz GG, and Acuna-Castroviejo D. A review of the evidence supporting melatonin's role as an antioxidant. J Pineal Res 18:1:1-11, 1995.
Reiter RJ, Oh CS, and Fujimori O. Melatonin: Its intracellular and genomic actions. Trends Endocrinol Metab 7:1:22-27, 1996.
Reiter RJ, Leppaluoto J. Melatonin as a hormone and an antioxidant: implications for organisms at high latitudes. Int J Circumpol Health 56:1-2: 4-11, 1997.
Reiter R, Tang L, Garcia JJ et al. Pharmacological actions of melatonin in oxygen radical pathophysiology. Life Sci 60: 25: 2255-2271,1997.
Reiter RJ. Antioxidant actions of melatonin. Adv Pharmacol 38:103-17, 1997.
Reiter RJ. Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol 56:3:359-384, 1998.
Reiter RJ, Tan D, Cabrera J, D'Arpa D, et al. The Oxidant/Antioxidant network: role of melatonin. Biol Signals Recept 8:1-2:56-63, 1999.
Rojdmark S, Wikner J et al. 5-fluorouracil attenuates an oncostatic effect of melatonin on estrogen-sensitive human breast cancer cells (MCF7). Cancer Lett 81(1):95-98, 1994.
Sack RL. et al. Morning vs evening light treatment for winter depresssion: Evidence that the therapeutic effects of light are mediated by circadian phase shifts. Arch Gen Psych 47, 343-351, April 1990.
Schernhammer Eva S., et al: Rotating Night Shifts and Risk of Breast Cancer in Women Participating in the Nurses' Health Study, J Natl Cancer Inst 2001 93: 1563-1568
Sheldon SH. Pro-convulsant effects of oral melatonin in neurologically disabled children. Lancet 351:1254, 1998.
Shida CS, Castrucci AML, and Lamy-Freund MT. High melatonin solubility in aqeous medium. J Pin Res 16:198-201, 1994.
Shirakawa S, Tsuchiya S, Tsutsumi Y, Kotorii T, et al. Time course of saliva and serum melatonin levels after ingestion of melatonin. Psych Clin Neurosc 52:2:266-267, 1998.
Singer C, Wild K, Sack R, and Lewy A. High dose melatonin is well tolerated by the elderly. Sleep Res 23:86, 1994.
Smythe GA, and Lazarus L. Growth hormone response to melatonin in man. Sci 184: 1373, 1974.
Stankov B, Fraschini F, and Oldani A. Melatonin and delayed sleep phase syndrome: Ambulatory polygraphic evaluation. Neuro Rep 6:132-134, 1994.
Stanley M and Brown GM. Melatonin levels are reduced in the pineal glands of suicide victims. Psychopharmacol 24(3):484-487, 1988.
Steinhilber D, Brungs M, and Carlberg C. The nuclear receptor for melatonin represses 5-lipoxygenase gene expression in human B-lymphocytes. J Biol Chem 270(13):7037-7040, 1995.
Tan DX, Chen LD, Poeggeler B, Reiter RJ, and Manchester LC. Melatonin: A potent, endogenous hydroxyl radical scavenger. Endocrinol J 1:57-60, 1993.
Tan DX, Poeggeler B, Reiter RJ, Chen LD, Chen S, Manchester LC, and Barlow-Walden LR. The pineal hormone melatonin inhibits DNA-adduct formation induced by the chemical carcinogen safrole in vivo. Cancer Let 70:1-2:65-71, 1993.
Tan DX, Reiter RJ, Chen LD, and Barlow-Walden LR. Both physiological and pharmacological levels of melatonin reduce DANN adduct formation induced by the carcinogen safrole. Carcinogen 15(2):215-218, 1994.
Tan DX, Manchester LC, Reiter RJ, Plummer BF, et al. A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation. Biochem Biophys Res Commun 253:3:614-620, 1998.
Terzolo M, Piovesan A, and Angeli A. Effects of long-term, low-dose, time-specified melatonin administration on endocrine and cardiovascular variables in adult men. J Pin Res 9:113-124, 1990.
Thompson C et al. Seasonal affective disorder and season-dependent abnormalities of melatonin suppression by light. Lancet 336, 703-706, Sept. 1990.
Touitou Y et al. Effect of a two hour early awakening of bright light exposure on plasma patterns of cortisol, melatonin, prolactin and testoterone in man. Acta endocrinol 126, 201-205, 1992.
Valcavi R, Zini M, Maestroni G, and Conti A. Melatonin stimulates growth hormone secretion through pathways other than the growth hormone-releasing hormone. Clin Endocrinol 39:193-199, 1993.
Van Vuuren RJ et al. Melatonin in human semen. South Afr Med J 73:375-376, 1988.
Vijayalaxmi BZ, Reiter RJ, Sewerynek E, Meltz ML, and Poeggeler B. Melatonin protects human blood lymphocytes from radiation induced chromosome damage. Mutat Res 346(1):23-31, 1995.
Viviani S, Bidoli P et al. Normalization of the light/dark rhythm of melatonin after prolonged subcutaneous administration of interleukin-2 in advanced small cell lung cancer patients. J Pin Res 12(3):114-117, 1992.
Voordouw B et al. Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. J Clin Endocr Metabol 74(1):108-117, 1992.
Wagner J, Wagner ML, and Hening WA. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother 32:6:680-91, 1998.
Waldhauser F, Waldhauser M, Lieberman HR, Deng MH, et al. Bioavailability of oral melatonin in humans. Neuroendocrinology 39:4:307-313, 1984.
Waldhauser F et al. Serum melatonin in central precocious puberty is lower than in age-matched prepubertal children. J Clin Endocr Metabol 73:793-796, 1991.
Weekley LB. Melatonin-induced relaxation of rat aorta: Interaction with adrenergic agonists. J Pin Res 11:28-34, 1991.
Wehr Ta. The durations of human melatonin secretion and sleep respond to the changes in daylenght (photoperiod). J Clin Endocrinol Metabol 73L6):1276-1280, 1991.
Wetterberg L. Melatonin in humans: Physiological and clinical studies. J Neur Transm Suppl. 13:289-310, 1978.
Wetterberg L, Aperia B, and Yuwiler A. Age, alcoholism and depression are associated with low levels of urinary melatonin. J Psych Neurosci 17(5):215-224, 1992.
Wright J, Aldhous M, and Arendt J. The effect of exogenous melatonin on endocrine function in man. J Clin Endocrinol 24:375-382, 1986.
Wright KP, Badia P, Myers BL, and Hakel M. Effects of caffeine, bright light, and their combination on nighttime melatonin and temperature during two nights of sleep deprivation. Sleep Res 24:458, 1995.
Yeleswaram K, McLaughlin LG, Knipe JO, and Schabdach D. Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications. J Pin Res 22:1:45-51, 1997.
Zhang H, Squadrito GL, Uppu R, and Pryor WA. Reaction of peroxynitrite with melatonin: A mechanistic study. Chem Res Toxicol 12:6:526-34, 1999.
Zhdanova IV, Wurtman RJ, Lynch HJ, Ives JR et al. Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther 57:5:552-558, 1995.
